Analystreport

Dicerna Pharmaceuticals Inc (NASDAQ: DRNA) is now covered by analysts at B. Riley. They set a "neutral" rating and a $10.00 price target on the stock.

Dicerna Pharmaceuticals, Inc.  (DRNA) 
Last dicerna pharmaceuticals, inc. earnings: 2/27 04:05 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.dicerna.com